H

HeartFlow

Biotech & Life Sciences · Redwood City, United States · Founded 2007 · IPO 2025

HeartFlow is a health technology startup that operates in the cardiovascular care market. The company has developed a non-invasive cardiac test that provides detailed visualization of a patient's coronary arteries. This innovative technology assists physicians in creating more effective treatment plans for their patients, thereby making cardiovascular care safer and easier. The company's primary clients are physicians and healthcare providers who are looking for safer, more efficient ways to diagnose and treat heart disease. HeartFlow's technology eliminates the need for invasive procedures, reducing both the risk to patients and the cost to healthcare providers. HeartFlow's business model is based on the sale of its proprietary technology. The company's HeartFlow Analysis, which includes the FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States and is commercially available in the United States and the United Kingdom. It is also approved in Japan and Canada. The company generates revenue by selling its technology to healthcare providers. It also likely earns income from ongoing service and maintenance contracts, as well as from updates and improvements to its technology. In summary, HeartFlow is a health tech startup that has developed a non-invasive cardiac test to assist physicians in diagnosing and treating heart disease. The company operates in the cardiovascular care market and generates revenue from the sale of its technology and related services. Keywords: Health Technology, Cardiovascular Care, Non-Invasive Cardiac Test, Coronary Arteries Visualization, Safer Diagnosis, Treatment Planning, FDA Clearance, Commercial Availability, Revenue Generation, Proprietary Technology.